Cargando…

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

BACKGROUND: FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadusta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Nan, Qian, Jiaqi, Chen, Jianghua, Yu, Xueqing, Mei, Changlin, Hao, Chuanming, Jiang, Gengru, Lin, Hongli, Zhang, Xinzhou, Zuo, Li, He, Qiang, Fu, Ping, Li, Xuemei, Ni, Dalvin, Hemmerich, Stefan, Liu, Cameron, Szczech, Lynda, Besarab, Anatole, Neff, Thomas B., Peony Yu, Kin-Hung, Valone, Frank H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837707/ https://www.ncbi.nlm.nih.gov/pubmed/28371815 http://dx.doi.org/10.1093/ndt/gfx011

Ejemplares similares

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
por: Li, Xuan, et al.
Publicado: (2018)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
por: Miao, A-Feng, et al.
Publicado: (2021)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells
por: Fujimaki, Ayaka, et al.
Publicado: (2023)

Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
por: Zhang, Pei, et al.
Publicado: (2018)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
por: Li, Xue, et al.
Publicado: (2022)

Osteoblast–Osteoclast Coculture Amplifies Inhibitory Effects of FG‐4592 on Human Osteoclastogenesis and Reduces Bone Resorption
por: Hulley, Philippa A, et al.
Publicado: (2020)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
por: Feng, Zhenlan, et al.
Publicado: (2022)

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways
por: Long, Guangfeng, et al.
Publicado: (2020)

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
por: Li, Axiang, et al.
Publicado: (2023)

Inhibition of HIF prolyl-4-hydroxylases by FG-4497 Reduces Brain Tissue Injury and Edema Formation during Ischemic Stroke
por: Reischl, Stefan, et al.
Publicado: (2014)

The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
por: Zhou, Muran, et al.
Publicado: (2019)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
por: Jiang, Yumin, et al.
Publicado: (2023)

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway
por: Li, Xue, et al.
Publicado: (2020)

Function and expression of prolyl hydroxylase 3 in cancers
por: Liu, Qiu-long, et al.
Publicado: (2013)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

The role of HIF prolyl hydroxylases in tumour growth
por: Jokilehto, Terhi, et al.
Publicado: (2010)

Hypoxia inducible factor prolyl hydroxylases in inflammatory bowel disease
por: Lun, Jie, et al.
Publicado: (2023)

Structure and Mechanism of a Viral Collagen Prolyl Hydroxylase
por: Longbotham, James E., et al.
Publicado: (2015)

Role of prolyl hydroxylase domain proteins in bone metabolism
por: Wolf, David, et al.
Publicado: (2022)

Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases
por: Kant, Ravi, et al.
Publicado: (2013)

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma
por: Hatzimichael, E, et al.
Publicado: (2012)

Prolyl-hydroxylase 3: evolving roles for an ancient signaling protein
por: Place, Trenton L, et al.
Publicado: (2013)

Role of prolyl hydroxylase domain proteins in the regulation of insulin secretion
por: Huang, Mei, et al.
Publicado: (2016)

Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
por: Yang, Ming, et al.
Publicado: (2014)

Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase
por: Yum, Soohwan, et al.
Publicado: (2017)

An Arabidopsis Prolyl 4 Hydroxylase Is Involved in the Low Oxygen Response
por: Konkina, Anna, et al.
Publicado: (2021)

Prolyl 3-Hydroxylase 2 Is a Molecular Player of Angiogenesis
por: Pignata, Paola, et al.
Publicado: (2021)

Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor
por: Wang, Ruth X., et al.
Publicado: (2021)

Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
por: Strowitzki, Moritz J., et al.
Publicado: (2021)

Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification
por: Negri, Armando Luis
Publicado: (2022)

Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk
por: Harlow, Charli E, et al.
Publicado: (2022)

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism
por: Ogawa, Chie, et al.
Publicado: (2023)

Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
por: Chou, Yu-Hsiang, et al.
Publicado: (2023)

Intrabody against prolyl hydroxylase 2 promotes angiogenesis by stabilizing hypoxia-inducible factor-1α
por: Zhao, Liangzhong, et al.
Publicado: (2019)

Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
por: Kiriakidis, Serafim, et al.
Publicado: (2017)

Sandwich ELISA for quantitative detection of human collagen prolyl 4-hydroxylase
por: Osmekhina, Ekaterina, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ctjnfnteugioa1j1774pe0t2o9